A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab
Open Access
- 1 December 2023
- journal article
- case report
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 16, 3503-3507
Abstract
Psoriasis is a chronic inflammatory cutaneous disease, affecting up to 3% of the worldwide population. Several clinical phenotypes can be distinguished. Among these, erythrodermic psoriasis (EP) is a rare and severe variant (less than 3% of cases), characterized by severe generalized erythema and scaling affecting at least 90% of the body surface area. EP is often a life-threatening condition, since several systemic symptoms (tachycardia, fever, fatigue, lymphadenopathy, dehydration, serum electrolyte disturbances) can be associated. Thus, a prompt and appropriate treatment is mandatory. Unfortunately, EP treatment is challenging. Indeed, the reduced prevalence of EP makes clinical trials feasibility difficult, leading to the absence of established guidelines. So, the treatment of EP is often derived from moderate-to-severe psoriasis management which relies on the use of conventional systemic drugs (cyclosporine, dimethyl fumarate, methotrexate, retinoids) and biologic agents. However, conventional systemic drugs are often contraindicated for patients’ comorbidities, or their use is characterized by reduced efficacy and various adverse events (AEs). The recent development of biologic drugs, which showed excellent results in terms of effectiveness and safety in plaque psoriasis, made these drugs an ideal weapon in EP management, despite their use in EP is still off-label. Among these, risankizumab, a humanized immunoglobulin G1 monoclonal antibody targeting the p19 subunit of the IL23, is one of the latest biologics approved for the management of moderate-to-severe psoriasis. Herein, we reported the first case of a caucasian patient affected by EP successfully treated with risankizumab, reaching PASI100 response after 16 weeks of treatment, without experiencing AEs.Keywords
This publication has 24 references indexed in Scilit:
- Long‐term safety of risankizumab from 17 clinical trials in patients with moderate‐to‐severe plaque psoriasis*British Journal of Dermatology, 2021
- Tildrakizumab: A new therapeutic option for erythrodermic psoriasis?Dermatologic Therapy, 2021
- Updates on the Treatment of Erythrodermic PsoriasisPsoriasis: Targets and Therapy, 2021
- EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situationsJournal of the European Academy of Dermatology and Venereology, 2021
- EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendationsJournal of the European Academy of Dermatology and Venereology, 2020
- Targeted Treatment for Erythrodermic Psoriasis: Rationale and Recent AdvancesDrugs, 2020
- Risankizumab for the treatment of psoriasisExpert Review of Clinical Pharmacology, 2019
- PsoriasisThe Lancet, 2015
- Pathogenesis and clinical features of psoriasisThe Lancet, 2007
- Psoriasis: epidemiology, clinical features, and quality of lifeAnnals of the Rheumatic Diseases, 2005